LBA52 Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD
Fizazi K, Mella P, Castellano D, Minatta J, Kalebasty A, Shaffer D, Limon J, Armstrong A, Lopez H, Sharkey B, Saci A, Li J, Wang X, Ciprotti M, Sathyanarayana P, Saad F, Petrylak D, Retz M, Pachynski R, Drake C. LBA52 Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD. Annals Of Oncology 2019, 30: v885-v886. DOI: 10.1093/annonc/mdz394.045.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerRadiographic progression-free survivalObjective response rateCastration-resistant prostate cancerBristol-Myers SquibbGenentech/RocheAssociation of biomarkersPersonal feesMeasurable diseaseProstate cancerGrade 3/4 treatment-related adverse eventsMedian radiographic progression-free survivalProstate-specific antigen (PSA) response rateResponse rateOngoing androgen deprivation therapyTreatment-related adverse eventsSafety of nivolumabAndrogen deprivation therapyPhase II studyPhase III trialsProgression-free survivalSanofi-AventisInterim analysis resultsMedical writing assistanceNon-financial support927P Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Hoffman-Censits J, Rosenberg J, van Der Heijden M, Dreicer R, Gracia J, Petrylak D, Retz M, Sabbatini R, Naglieri E, Caserta C, Maruzzo M, Iacovelli R, Galli L, McDermott R, Barrera R, Bonfill T, De Ducla S, Ding B, Linsenmeier J, Sternberg C. 927P Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC). Annals Of Oncology 2019, 30: v372-v373. DOI: 10.1093/annonc/mdz249.026.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaBody mass indexF. Hoffmann-La RochePersonal feesBristol-Myers SquibbHoffmann-La RocheCohort 1Roche/GenentechMedian body mass indexSeattle GeneticsMedian treatment durationObjective response rateSignificant OS differenceOverall survival outcomesDifferent treatment settingsSignificant differencesBristol-Meyers SquibbAtezolizumab monotherapyECOG PSFortress BiotechMale ptsMedian OSOS benefitWeill Cornell MedicineTreatment discontinuation929P Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg C, Matsubara N, Nishiyama H, Castellano D, Hussain S, Bamias A, Hozak R, Rhodes R, Xia M, Rasmussen E, Aggarwal A, Wijayawardana S, Bell-McGuinn K, Drakaki A. 929P Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study. Annals Of Oncology 2019, 30: v373-v374. DOI: 10.1093/annonc/mdz249.028.Peer-Reviewed Original ResearchCombined positive scorePD-L1 statusPersonal feesHazard ratioBasal subtypeMolecular subtypesEli LillyPD-L1 combined positive scorePlatinum-refractory urothelial carcinomaPositive PD-L1 statusTumor cellsSeattle GeneticsExploratory biomarker analysisImmune cell stainingPD-L1 groupRefractory urothelial cancerImproved overall survivalPD-L1 antibodiesPD-L1 immunohistochemistryClaudin-low subtypeRefractory urothelial carcinomaUrothelial carcinoma molecular subtypesArchival tumor tissueBiomarker analysisMedian OS